12 Best Foreign Stocks to Buy Right Now

7. ICON Public Limited Company (NASDAQ:ICLR)

Stock Upside: 50.97%

Number of Hedge Fund Holders: 43

ICON Public Limited Company (NASDAQ:ICLR) is one of the best foreign stocks to buy right now. On February 12, TD Cowen reiterated its Hold rating and $183 price target on ICON Public Limited Company (NASDAQ:ICLR) after the company launched an independent probe into revenue recognition practices.

Preliminary findings suggest less than a 2% revenue overstatement in 2023–2024, leading ICON to withdraw 2025 guidance. While management expects to conclude the review by April 30, TD Cowen estimates the impact at about 13% and 12% on adjusted EPS for 2023 and 2024, respectively, and noted the 35% share price drop looks “overdone,” though the investigation remains an overhang.

Independently of the analyst action, on February 12, ICON announced it will delay releasing its fourth quarter and full year 2025 earnings results. The company now plans to publish them on or before April 30, 2026.

According to ICON, its Audit Committee initiated an internal investigation in late October 2025 into certain accounting practices and controls after concerns were reported through company management. This investigation, said ICON, is being conducted by outside legal counsel with support from forensic and technical accounting firms.

ICON said the investigation is focused primarily on revenue recognition practices for fiscal years 2023 through 2025. It will examine how and when the company recorded revenue in those years. The company detailed that preliminary indications from the investigation suggest that its reported revenue for 2023 and 2024 may have been overstated by less than 2% in each fiscal year.

As part of the review of accounting practices and internal controls, ICON expects to report one or more material weaknesses in its internal control over financial reporting. Also, because of the investigation and resulting delay in completing its normal reporting processes, the company withdrew its previously issued full year 2025 financial guidance. It said it is not yet able to communicate its 2025 financial performance.

ICON Public Limited Company (NASDAQ:ICLR) is an Irish company. It provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. Its offerings include clinical trial management, laboratory services, and consulting.